Renovaro Biosciences Inc. (RENB)
| Market Cap | 330.44M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -41.23M |
| Shares Out | 143.67M |
| EPS (ttm) | -0.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 127,344 |
| Open | 2.250 |
| Previous Close | 2.220 |
| Day's Range | 2.130 - 2.380 |
| 52-Week Range | 0.393 - 5.250 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 10, 2024 |
About RENB
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer;... [Read more]
Financial Performance
Financial StatementsNews
Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distingui...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renovaro Biosciences Inc. - RENB
NEW YORK, March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Renovaro Biosciences Inc. ("Renovaro" or the "Company") (NASDAQ: RENB). Such investors are adv...
ROSEN, LEADING INVESTOR COUNSEL, Encourages Renovaro Biosciences Inc. Investors to Inquire About Securities Class Action Investigation - RENB
NEW YORK , Feb. 25, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Renovaro Biosciences ...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Renovaro Biosciences Inc. Investors to Inquire About Securities Class Action Investigation - RENB
NEW YORK , Feb. 16, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Renovaro Bioscie...
Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.
Statement of Renovaro Inc
LOS ANGELES, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The following is a statement by Renovaro (Nasdaq: RENB) in response to Hindenburg's recent opinion piece:
ROSEN, A LEADING NATIONAL FIRM, Encourages Renovaro Biosciences Inc. Investors to Inquire About Securities Class Action Investigation – RENB
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Renovaro Biosciences Inc. (NAS...
AI Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine
LOS ANGELES, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB) announced today that it completed its acquisition of GEDi Cube Intl Ltd. (“GEDiCube”). Renovaro, which means renew, combines...
Renovaro Biosciences Announces Results of Special Meeting of Shareholders
LOS ANGELES, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB) (the “Company”), a biotechnology corporation focusing on cell, gene, and immunotherapy, announced today the resu...
Message from Renovaro Bioscience, Inc.'s CEO, The Hon. Mark Dybul, MD
Accelerating Healthcare With Award-Winning AI: Big Steps Forward In 2023 And The Early Days Of 2024 Accelerating Healthcare With Award-Winning AI: Big Steps Forward In 2023 And The Early Days Of 2024
RENOVARO BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Renovaro Biosciences Inc. - RENB
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Renovaro Biosc...
Avram Miller, Co-Founder of Intel Capital, Joins Renovaro Biosciences Board of Directors
LOS ANGELES, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB)(Renovaro), a biotechnology corporation focusing on cell, gene, and immunotherapy, has announced that Avram Mille...
Renovaro Biosciences Appoints Two Finance Industry Experts to Board of Directors
LOS ANGELES, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB)(Renovaro), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy focused on solid tumors...
Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD
AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine
AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine
Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD LOS ANGELES, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (Nasdaq: RENB) Dear Shareholders, I am writing to provide you wi...
RENB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Renovaro Biosciences Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Renovaro Biosciences Inc. (NASDAQ: RENB) and GEDi Cube Intl Ltd. is fair to Renovaro sh...
Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive Agreement to Combine
The combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better targeted treatments, a...
GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine
LOS ANGELES & AMSTERDAM--(BUSINESS WIRE)--GEDi Cube Intl Ltd. (GEDi Cube), an AI medical technology company, and Renovaro Biosciences Inc. (NASDAQ:RENB) (Renovaro), an advanced, preclinical biotechnol...
Renovaro BioSciences Welcomes GEDiCube Announcement of New Joint Effort
LOS ANGELES, Aug. 30, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RENB). Renovaro BioSciences congratulates GEDiCube on their joint effort to work to accelerate early diagnosis of cancer in clinical trials.
Renovaro BioSciences Congratulates GEDi Cube on Appointment of its Chief Medical Officer
LOS ANGELES, Aug. 21, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RENB). Renovaro BioSciences congratulates GEDi Cube on its appointment of Dr. Lester Russell as Chief Medical Officer. For more information: (ht...
AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer
LOS ANGELES, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Renovaro BioSciences Inc. (NASDAQ:RENB) (formerly NASDAQ: ENOB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on ...
Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder Meeting
LOS ANGELES, June 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc., a company developing gene-modified cell immunotherapies for cancer and infectious diseases, wishes to advise t...
Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review
LOS ANGELES, June 08, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application (IND) f...
Enochian BioSciences' CEO Letter to Shareholders
Turning the Page; A Promising Future Turning the Page; A Promising Future
Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher
LOS ANGELES, March 29, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the “Company”) announces that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy f...